Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential
I'm PortAI, I can summarize articles.
Ram Selvaraju from H.C. Wainwright has reiterated a Buy rating on Aquestive Therapeutics, setting a price target of $10.00. This rating is driven by the anticipated FDA approval of Anaphylm, a non-invasive epinephrine product for severe allergic reactions, expected by January 31, 2026. The product's potential peak sales could exceed $280 million by 2034, supported by strategic preparations for its launch. Piper Sandler also maintains a Buy rating with an $8.00 price target. Selvaraju has a 23.3% average return and a 51.40% success rate on his recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments